A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study

A.K.L. Reyners, L. de Munck, F.L.G. Erdkamp, W.M. Smit, K. Hoekman, R.I. Lalisang, H. de Graaf, A.N.M. Wymenga, M. Polee, H Hollema, M.A.T.M. van Vugt, M. Schaapveld, P.H.B. Willemse

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)2896-2902
JournalAnnals of Oncology
Issue number11
Publication statusPublished - 2012

Cite this